Month: December 2020

Palvella Therapeutics Reports Top-Line Results from Pivotal Phase 2/3 VALO Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel in Patients with Pachyonychia Congenita

~ VALO Study Misses Primary Endpoint in Phase 3 Randomized Withdrawal Portion ~ ~ VALO Study Achieves Primary Endpoint in...

Therma Bright Signs IR Agreement with Barwicki Investor Relations, Adds $300,000 to Treasury Through Exercise of Warrants and Options; and Grants Options

Toronto, Ontario--(Newsfile Corp. - December 24, 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical...

Jaguar Health Signs Second Agreement for $6 Million Non-dilutive Financing Transaction Involving the Sale of Royalty Rights Related to Future Mytesi (Crofelemer) and Lechlemer Revenue Stream

No royalty payments due for 18-24 months Proceeds will be allocated to support regulatory activities associated with the Company's development...

error: Content is protected !!